ProPhase Labs, Inc.
AI Executive Summary
AI-powered analysis of 10-Q filing content
ProPhase Labs shows severe liquidity distress with only ~$20,000 in cash against $5.7 million in debt, ineffective disclosure controls, and multiple concurrent legal proceedings including a qui tam False Claims Act suit against bankrupt diagnostic subsidiaries, an arbitration alleging default on a convertible note, and a genetic privacy class action. The filing is a 10-Q/A (amended), and the combination of near-zero cash, bankruptcy of key subsidiaries, and going-concern-like debt servicing risk language indicates significant deterioration in financial condition and internal control reliability.
Red Flags Detected (6)
Only approximately $20,000 in cash and cash equivalents against $5.7 million in outstanding debt
Disclosure controls and procedures concluded to be ineffective as of June 30, 2026
Diagnostic subsidiaries filed Chapter 11 bankruptcy petitions (September 22, 2025) and are named defendants in a qui tam False Claims Act action
3 more red flags detected
Key Takeaways
Company's cash position ($20K) is critically low relative to its $5.7M debt load, signaling acute liquidity risk
Ineffective disclosure controls raise concerns about financial reporting accuracy, consistent with this being a 10-Q/A filing
3 more takeaways
Filing Overview
What This Means
High Risk Filing: This company is showing signs of financial stress or significant operational challenges.
Deteriorating Trend: Conditions are worsening compared to previous filings. This may create opportunities for service providers.
Quarterly Report: Interim filing with unaudited financial data for the quarter.